← Human Trials & Peer-Reviewed Studies
A Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy Subjects
Plain-language guide to NCT07285863: phase 4 interventional trial of Secretin, 24 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT07285863
- Phase
- phase 4
- Status
- recruiting participants
- Start
- 2026-03-11
- Completion (planned or actual)
- 2027-03
- Participants
- 24 (estimated)
- Design
- na, open label (everyone knows who gets what), other
- Conditions studied
- Exocrine Pancreatic Insufficiency; Chronic Pancreatitis
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
In this phase 4 trial, researchers set out to test Secretin.
The purpose of this study is to collect pancreas fluid from the duodenum using the endoscopic pancreas function collection method in healthy participants after pancreatic stimulation with human secretin.
It had 1 arm (groups): Healthy Participants (experimental).
The registry classes the interventions as drug.
Who Took Part
24 planned participants were the target.
It was open to people of any sex aged from 18 years up to 80 years.
Healthy volunteers could join, not only people with the condition.
Examples of who could join: Males or non-pregnant females. Participants must be in good health based on medical history (ASA Class 3 or below). Participants must be willing and able to provide informed consent. Receiving an endoscopic ultrasound for a non-pancreatic indication.
The full record lists 5 inclusion and 9 exclusion criteria; among the exclusions: history of any form of pancreatitis and/or other pancreatic diseases (e.g. pancreatic cysts, pancreatic masses); history of inflammatory bowel disease; history of vagotomy.
How the Study Was Run
The set-up was single-group and open-label.
Nothing was hidden in this open-label Secretin study: the participants and staff both knew the treatment.
Everyone received the same intervention, so there was no separate comparison group inside the trial.
It started in 2026-03-11 with completion listed for 2027-03.
It ran at 1 site in United States.
Its stated primary purpose is other.
What Was Measured
Researchers chose this as the main measure: Pancreatic Fluid Bicarbonate Composition (time frame: 5, 10, 15, and 20-minutes post-secretin administration). Pancreatic Fluid Sodium Composition (time frame: 5, 10, 15, and 20-minutes post-secretin administration). Pancreatic Fluid Potassium Composition (time frame: 5, 10, 15, and 20-minutes post-secretin administration).
What This Means in Plain Language
Put simply, this is a phase 4 trial of Secretin in 24 people.
Its size is small, so on its own it can only give an early look.
It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Secretin compound page, all human trials.
Our Notes on the Compound
Secretin: A 27-amino-acid gut hormone that triggers pancreatic secretion; used as a diagnostic agent in pancreatic function testing.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.